Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


MSAC scrutinises blood market

Posted 9 October 2019

The MSAC is conducting a cost-effectiveness review of all immunoglobulin products supplied through the National Blood Authority (NBA) after use of the products jumped in the past decade. 

Demand for immunoglobulin has increased 11 per cent since 2009-10, shooting Australia into the top three users of immunoglobulin along with much bigger countries such as the US and Canada, the MSAC said.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios